For Publishers
DiscoveryMetadataPeer reviewHostingPublishing
For Researchers
JoinPublishReviewCollect
Register
Blog
About
Search
Advanced search
My ScienceOpen
Search
For Publishers
For Researchers
Blog
About
3
views
0
references
 Top references
cited by
0
    
0 reviews
 Review
0
comments
 Comment
0
recommends
+1 Recommend
0 collections
    0
    shares
      1,012
      similar
       All similar
      • Record: found
      • Abstract: not found
      • Article: not found

      A Matching-adjusted Indirect Comparison (MAIC) of Bortezomib-Thalidomide-Dexamethasone (VTd) and Daratumumab Plus VTd (D-VTd) Versus Bortezomib-Dexamethasone (Vd) in Patients with Newly Diagnosed Multiple Myeloma (NDMM) who are Transplant Eligible (TE)

      Read this article at

      ScienceOpenPublisher
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Related collections

          Author and article information

          Journal
          Title: Clinical Lymphoma Myeloma and Leukemia
          Abbreviated Title: Clinical Lymphoma Myeloma and Leukemia
          Publisher: Elsevier BV
          ISSN (Print): 21522650
          Publication date Created: October 2019
          Publication date (Print): October 2019
          Volume: 19
          Issue: 10
          Pages: e200-e201
          Article
          DOI: 10.1016/j.clml.2019.09.334
          SO-VID: 537b31ba-9d09-4d00-aabf-a7192b2748b8
          Copyright © © 2019
          License:

          https://www.elsevier.com/tdm/userlicense/1.0/

          History

          Data availability:

          Comments

          Comment on this article